BioM?rieux (BMXMF) Stock Rating Lowered by Zacks Investment Research

BioM?rieux (OTCMKTS:BMXMF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “bioMérieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioMérieux S.A. is based in Marcy L Etoile, France. “

How to Become a New Pot Stock Millionaire

Shares of BioM?rieux stock opened at $78.95 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.82 and a debt-to-equity ratio of 0.23. BioM?rieux has a 1-year low of $78.00 and a 1-year high of $248.00.

TRADEMARK VIOLATION WARNING: “BioM?rieux (BMXMF) Stock Rating Lowered by Zacks Investment Research” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3294644/biom%ef%bf%bdrieux-bmxmf-stock-rating-lowered-by-zacks-investment-research.html.

BioM?rieux Company Profile

bioMérieux SA provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company offers reagents, instruments, software, and services for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products.

Receive News & Ratings for BioM?rieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioM?rieux and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Scorpio Bulkers  Earns Daily Coverage Optimism Score of 0.11
Scorpio Bulkers Earns Daily Coverage Optimism Score of 0.11
Calumet Specialty Products Partners  Given Coverage Optimism Rating of 0.18
Calumet Specialty Products Partners Given Coverage Optimism Rating of 0.18
Limelight Networks  Earning Somewhat Positive Media Coverage, Study Shows
Limelight Networks Earning Somewhat Positive Media Coverage, Study Shows
Reviewing SSAB Svenskt Stal  and Haynes International
Reviewing SSAB Svenskt Stal and Haynes International
Head-To-Head Comparison: Minerals Technologies  & Luxfer
Head-To-Head Comparison: Minerals Technologies & Luxfer
Enova International  versus Credit Acceptance  Head to Head Contrast
Enova International versus Credit Acceptance Head to Head Contrast


© 2006-2018 Ticker Report. Google+.